November is Hyperhidrosis Awareness Month

Dermira supports the hyperhidrosis community—from the more than 15 million patients in the US who suffer from excessive sweating to the advocates and healthcare professionals who care for them.

LEARN MORE
NP-US-NON-0566 10/2020
MENU MENU

About Us

We are looking deeper.

Dermira, a wholly-owned subsidiary of Eli Lilly and Company, is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology. We are focused on delivering important new therapies to the millions of patients living with chronic skin conditions.

Dermira is committed to understanding and addressing the needs of both patients and physicians. We are using our experience and insight to identify and develop leading-edge medical dermatology clinical programs. Our goal is to help transform the way skin conditions are treated by serving as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology.

Our History, at a Glance

2020
  • Acquisition is complete and Dermira becomes wholly-owned subsidiary of Eli Lilly and Company
  • Dermira enters into a definitive agreement with Eli Lilly and Company for the acquisition of Dermira, Inc.
2019
  • Dermira initiates a Phase 3 program evaluating the safety and efficacy of lebrikizumab in adult and adolescent patients ages 12 and older with moderate-to-severe atopic dermatitis
  • Almirall exercises its option to license rights to develop and commercialize lebrikizumab for the treatment of atopic dermatitis in Europe
  • Dermira announces positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis
  • Dermira and Almirall enter into option and license agreement for European rights to lebrikizumab
2018
  • QBREXZA® (glycopyrronium) cloth is available for prescribing in the United States
  • The FDA grants approval for Dermira’s first medication, QBREXZA® (glycopyrronium) cloth
  • Dermira announces the Phase 3 program for olumacostat glasaretil (formerly DRM01) did not meet its co-primary endpoints in patients with acne vulgaris and discontinues this program
  • Dermira initiates a Phase 2b dose-ranging study assessing lebrikizumab in adult patients with moderate-to-severe atopic dermatitis in January 2018
2017
  • Dermira and UCB announce that the companies agreed to end a development and commercialization agreement for CIMZIA (certolizumab pegol) in psoriasis
  • Dermira acquires the exclusive, worldwide rights to develop and commercialize lebrikizumab for atopic dermatitis and other potential indications pursuant to a licensing agreement with Roche
  • Dermira raises $278 million through a convertible debt financing
  • Dermira raises $182 million through a follow-on equity financing
  • Dermira announces positive results from CIMPACT, the final Phase 3 CIMZIA® trial in patients with moderate-to-severe chronic plaque psoriasis
  • Dermira begins a Phase 3 program for olumacostat glasaretil (formerly DRM01) in patients with acne vulgaris
2016
  • Dermira reaches a market value of $1 billion+
  • Dermira begins a Phase 3 program for olumacostat glasaretil (formerly DRM01) in patients with acne vulgaris
  • Dermira announces positive topline results from CIMPASI-1 and CIMPASI-2, the first two trials from the Phase 3 clinical program evaluating CIMZIA as a potential treatment option for patients with moderate-to-severe chronic plaque psoriasis
  • Dermira raises $136 million through a follow-on equity financing
  • Dermira announces positive topline results from the Phase 3 clinical program evaluating glycopyrronium tosylate (formerly DRM04) as a potential treatment option for patients with primary axillary hyperhidrosis
  • Dermira announces topline results from the Phase 2b program evaluating olumacostat glasaretil in patients with acne vulgaris
2015
  • Dermira raises $104 million through a follow-on equity financing
  • Dermira begins a Phase 3 program for glycopyrronium tosylate in patients with primary axillary hyperhidrosis
  • Dermira begins a Phase 2b program for olumacostat glasaretil in patients with acne vulgaris
2014
  • Dermira begins a Phase 3 program for CIMZIA in patients with moderate-to-severe chronic plaque psoriasis
  • Dermira goes public, raising $113 million, and is listed on NASDAQ as DERM
  • Dermira raises $49 million in a Series C financing from existing investors and new healthcare-focused funds
  • Dermira enters into a collaboration agreement with UCB S.A. to develop and commercialize CIMZIA as a treatment for patients with moderate-to-severe chronic plaque psoriasis
2013
  • Dermira raises $35 million in a Series B financing with investments from Osaka-based Maruho Co., Ltd., a leading dermatology company in Japan, and existing investors Bay City Capital, New Enterprise Associates and Canaan Partners
2012
  • Dermira initiates hyperhidrosis development program
2011
  • Dermira raises $34 million in a Series A financing with investments from Bay City Capital, New Enterprise Associates and Canaan Partners
  • Dermira acquires olumacostat glasaretil, a topical product candidate as a potential treatment for acne vulgaris
2010
  • Dermira is founded in Redwood City, Calif., with $1 million in funding from Bay City Capital